Related Experiment Video
Updated: Sep 10, 2025

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
The physiologic and psychologic effects of glucagon-like peptide-1 receptor agonists
Sarah A Browne-Bradwisch1, Erin Murphy Smith, Catherine Wilson-Mooney
1At Kingsborough Community College in Brooklyn, N.Y., Sarah A. Browne-Bradwisch is a Professor and Jonas Veterans Scholar; Erin Murphy Smith is a Professor; Catherine Wilson-Mooney is an Assistant Professor and Co-Deputy chairperson of Clinical Affiliations; and Courtney Donahue-Stathis is an Assistant Professor and Co-Deputy chairperson of Clinical Affiliations.
Abstract:
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence as well as its associated complications, the need for adequate treatment strategies for this chronic disease has never been higher. GLP-1 RAs have beneficial effects in treating T2D. This article discusses updates on the safety and effectiveness of GLP-1 RAs for obesity and many related conditions.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Hypoglycemia and Glucagon
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Glinides
GPCRs Regulate Adenylyl Cylase Activity
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

